Liver enzymes (ALT, AST, γGT) were decreased in the sema 2.4 mg group and in the sema 1.0 mg group; In overweight or obese with T2DM, sema 2.4 mg achieved a clinically meaningful decrease in bodyweight compared with placebo. The gene discussed is GPT; the disease is type 2 diabetes mellitus.